FOXP3 and neoplasm: Pu et al. have identified an integrated immune ratio based on the number of infiltrating CD8+ T cells and FOXP3+ Tregs to predict tumour suppression in the combination immunotherapy of CD25, TGF-β, and PD-1 blockade [174].